Help | RSS Feed

Jazz Pharmaceuticals, Inc. (NASD:JAZZ) Seasonal Chart

Seasonal Chart Analysis

Analysis of the Jazz Pharmaceuticals, Inc. (NASD:JAZZ) seasonal charts above shows that a Buy Date of April 22 and a Sell Date of August 19 has resulted in a geometric average return of 26.48% above the benchmark rate of the S&P 500 Total Return Index over the past 12 years. This seasonal timeframe has shown positive results compared to the benchmark in 10 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 12 years by an average of 15.22% per year.

The seasonal timeframe is Inline with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz’s product portfolio includes its lead drug, Xyrem, for narcolepsy, as well as Erwinaze for acute lymphoblastic leukemia, Defitelio for severe veno-occlusive disease after stem cell transplant, and Vyxeos for acute myeloid leukemia.

To download JAZZ seasonal chart data, please log in or Subscribe.


Stocks mentioned in this post:

    Search Seasonal Charts by Symbol, Company, or Term

   Symbols by Letter: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z